ImmunityBio, Inc.’s IBRX share price has dipped by 6.65%, which has investors questioning if this is right time to buy.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive NMIBC in papillary ...

ImmunityBio announces US FDA submissions of sBLA for NMIBC papillary disease and EAP for Anktiva to treat lymphopenia: Culver City, Calif Thursday, April 17, 2025, 15:00 Hrs [IST] ...

The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive NMIBC in papillary ...

CULVER CITY, Calif. - ImmunityBio, Inc. (NASDAQ: IBRX), a biotechnology firm specializing in immunotherapy, reported a significant increase in sales and has made key regulatory submissions to the ...

Highlights,Institutional allocation shifts observed, with Corebridge Financial Inc. lowering its exposure to ImmunityBio in the fourth quarter.,ImmunityBio opened at a relatively lower price compared ...

CULVER CITY, Calif. - ImmunityBio, Inc. (NASDAQ: IBRX), a biotechnology firm specializing in immunotherapy, reported a significant increase in sales and has made key regulatory submissions to the U.S.

We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look ...

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...